We describe a protocol for a three-dimensional co-culture model of infected airways, using CFBE41o– cells, THP-1 macrophages, and Pseudomonas aeruginosa, established at the air-liquid interface. This model provides a new platform to simultaneously test antibiotic efficacy, epithelial barrier function, and inflammatory markers.
fDrug research for the treatment of lung infections is progressing towards predictive in vitro models of high complexity. The multifaceted presence of bacteria in lung models can re-adapt epithelial arrangement, while immune cells coordinate an inflammatory response against the bacteria in the microenvironment. While in vivo models have been the choice for testing new anti-infectives in the context of cystic fibrosis, they still do not accurately mimic the in vivo conditions of such diseases in humans and the treatment outcomes. Complex in vitro models of the infected airways based on human cells (bronchial epithelial and macrophages) and relevant pathogens could bridge this gap and facilitate the translation of new anti-infectives into the clinic. For such purposes, a co-culture model of the human cystic fibrosis bronchial epithelial cell line CFBE41o– and THP-1 monocyte-derived macrophages has been established, mimicking an infection of the human bronchial mucosa by P. aeruginosa at air-liquid interface (ALI) conditions. This model is set up in seven days, and the following parameters are simultaneously assessed: epithelial barrier integrity, macrophage transmigration, bacterial survival, and inflammation. The present protocol describes a robust and reproducible system for evaluating drug efficacy and host responses that could be relevant for discovering new anti-infectives and optimizing their aerosol delivery to the lungs.
Pseudomonas aeruginosa is a relevant pathogen in cystic fibrosis (CF) that contributes to lung tissue impairment1. The production of polysaccharides, such as alginate and other mucoid exopolysaccharides, coordinates the progress of the disease, which leads to tenacious bacterial adherence, limits the delivery of antibiotics to bacteria and protects the bacteria against the host immune system2. The transition of P. aeruginosa from the planktonic stage to biofilm formation is a critical issue in this context, also facilitating the occurrence of antibiotic tolerance.
In the context of CF, the mouse has primarily been used as a model. Mice, however, do not spontaneously develop this disease with the introduction of CF mutations3. Most of the bacterial biofilm development and drug susceptibility studies have been performed on abiotic surfaces, such as Petri dishes. However, this approach does not represent the in vivo complexity. For instance, important biological barriers are absent, including immune cells as well as the mucosal epithelium. Though P. aeruginosa is quite toxic to epithelial cells, some groups have managed to co-cultivate an earlier P. aeruginosa biofilm with human bronchial cells. These cells originated from cystic fibrosis patients with CFTR mutation (CFBE41o– cells)4 and allowed to assess antibiotic efficacy5 or assess the correction of the CFTR protein during infection6. Such a model was shown to improve the predictability of drug efficacy, in addition to enabling characterization of issues with drugs that failed in later phases of drug development7.
However, in the lung, the mucosal epithelium is exposed to air. Moreover, immune cells present in the airways, like tissue macrophages, play an essential role against inhaled pathogens or particles8. Macrophages migrate through the different cell layers to reach the bronchial lumen and fight the infection. Furthermore, inhaled drugs also have to cope with the presence of mucus as an additional non-cellular element of the pulmonary air-blood barrier9. Indeed, several complex three-dimensional (3D) in vitro models have been developed, aiming to increase the in vivo relevance. Co-culture systems not only increase the complexity of in vitro systems for drug discovery but also enable to study cell-cell interactions. Such complexity has been addressed in studies about macrophage migration10, the release of antimicrobial peptides by neutrophils11, the role of mucus in infection9, and the epithelial cell reaction to excessive damage12. However, a reliable CF-infected in vitro model that features the genetic mutation in CF, that is exposed to the air (increased physiological condition), and integrates immune cells is still lacking.
To bridge this gap, we describe a protocol for stable human 3D co-culture of the infected airways. The model is constituted of human CF bronchial epithelial cells and macrophages, infected with P. aeruginosa and capable of representing both a diffusional and immunological barrier. With the goal of testing anti-infectives at reasonably high throughput, this co-culture was established on the permeable filter membrane of well plate inserts, using two human cell lines: CFBE41o– and THP-1 monocyte-derived macrophages. Moreover, to eventually study the deposition of aerosolized anti-infectives13, the model was established at the air-liquid interface (ALI) rather than liquid covered conditions (LCC).
As we report here, this model allows assessing not only bacterial survival upon an antibiotic treatment but also cell cytotoxicity, epithelial barrier integrity, macrophage transmigration, and inflammatory responses, which are essential parameters for drug development.
This protocol combines two relevant cell types for inhalation therapy of the pulmonary airways: macrophages and CF bronchial epithelium. These cells are seeded on opposite sides of permeable support inserts, allowing cell exposure to air (called the air-liquid interface (ALI) conditions). This co-culture of host cells is subsequently infected with P. aeruginosa. Both host cell lines are of human origin: the epithelial cells represent the cystic fibrosis bronchial epithelium, with a mutation on the CF channel (CFBE41o–), and the THP-114 cells are a well-characterized macrophage-like cell line. A confluent epithelial layer is first allowed to form on the upper side of well plate inserts before the macrophage-like cells are added to the opposite compartment. Once the co-culture is established at ALI, the system is inoculated with P. aeruginosa at the apical side. This infected co-culture system is then used to assess the efficacy of an antibiotic, e.g. tobramycin. The following end-points are analyzed: epithelial barrier integrity in terms of transepithelial electrical resistance (TEER), visualization of cell-cell and cell-bacteria interactions by confocal laser scanning microscopy (CLSM), bacterial survival by counting of colony-forming units (CFU), host cell survival (cytotoxicity) and cytokine release.
1. Growth and differentiation of cells in permeable support inserts
2. Establishment of an epithelial-macrophage co-culture on permeable supports
3. Infection by P. aeruginosa
NOTE: All following steps from here must be done in a biosafety level 2 (BSL2) laboratory.
4. Sample preparation for confocal laser-scanning microscopy (CLSM)
5. Measurement of bacterial proliferation via colony-forming units (CFU)
6. Evaluation of cell cytotoxicity via lactate dehydrogenase assay
7. Assessing the release of human cytokines
Figure 1A shows the morphology of the resulting co-culture of human bronchial epithelial cells and macrophages after growing both for 24 h on the apical and basolateral side of permeable supports, respectively. The epithelial barrier integrity is shown by higher TEER (834 Ω×cm2) and CLSM by immunostaining for the tight junction protein ZO-1 (Figure 1B). The same results observed in terms of barrier integrity of uninfected CFBE41o– monoculture could be seen in the uninfected epithelial-macrophage co-cultures.
To model a bacterial infection, P. aeruginosa was inoculated at a multiplicity of infection (MOI) of 1:1 on CFBE41o– cells. Six hours after infection (Figure 2A), macrophages were observed on the apical side of the co-culture. After the infection, the TEER dropped from 834 to 250 Ω×cm2, indicating a compromised epithelial barrier, as also visualized by ZO-1 staining (Figure 2B).
Figure 3 shows macrophage transmigration through the permeable membrane pores and bacteria uptake by THP-1 cells on the apical side. The samples were fixed at 1, 3, and 6 h post-incubation from independent experiments. In the THP-1 monocultures (Figure 3A–C), macrophages migration was observed as early as 1 h, while in the co-culture (Figure 3D–F), this was seen after 3 h infection. Bacteria uptake in THP-1 was observed after 3 h of infection, in both monoculture and co-culture. No bacterial uptake by CFBE41o- could be seen. Cross-sectional views were placed such that the permeable membrane support was in the middle as a separation of the apical and basolateral compartment.
Figure 4 shows confocal scanning laser microscopy pictures of infected co-cultures (CFBE41o– + THP-1) treated with or without tobramycin for 6 h (Figure 4A, B) or 20 h (Figure 4C,D). Without treatment, both the epithelial cells and the macrophages died after 20 h of infection (Figure 4C). However, upon tobramycin treatment, the host cells are preserved after 20 h; still, some bacteria can be observed in the culture. Despite being seen after 6 h of treatment in the microscopy pictures (Figure 4B), the bacteria did not proliferate as observed in CFU assays in Figure 4E. Nevertheless, after 20 h treatment, the bacteria recovered the proliferation capability, as seen by the colonies in the CFU assay (Figure 4F). The cell lysis protocol with cold water and scraping can release bacteria attached and possibly internalized in cells. At the same time, the cells are destroyed (Supplementary Figure S1A, B). The centrifugation steps used in this paper for epithelial cells (300 x g) or bacteria (21,250 x g) did not hamper the viability of both (Supplementary Figures S1C, D). All CFU assays were performed by freezing the samples at -20°C, followed by thawing and plating. This procedure reduced the number of bacteria by 2-logs, compared to fresh samples (Supplementary Figure S1E). As this procedure is done simultaneously for all experimental groups (treated and untreated) at different time points, this reduction will be incorporated in the final results (Supplementary Figure S1E). Moreover, the concentration of tobramycin used here showed no toxicity for the uninfected cells (Supplementary Figure S2A) and also no further inflammatory response (Supplementary Figure S2B). However, it was within the range of the minimum inhibitory concentration to kill P. aeruginosa.
Figure 5 shows the transepithelial electrical resistance (TEER) and cell viability. Figure 5A–B illustrates the TEER of monocultures and co-cultures. The co-culture of CFBE41o– cells with THP-1 did not induce any change in the epithelial barrier integrity compared to the monoculture (red bars). Upon the infection, the TEER value dropped (green bar). After 1 h of infection, some samples were treated with the antibiotic tobramycin (blue bar), for 6 or 20 h. The treatment preserved the epithelial barrier integrity, as observed by the higher TEER. Figure 5C shows the percentage of LDH release as an indication of cell toxicity upon infection and tobramycin treatment after 6 h. The co-culture itself induced a release of LDH, which was the same for the infected cells (around 20%). After 20 h of infection, no signal of LDH could be detected. To prove LDH reliability for long-term infection, PAO1-GFP was incubated in medium with and without LDH 1 U/mL compared to respective uninfected controls (Supplementary Figure S2C). The LDH signal was lost after prolonged incubation (20 h) with P. aeruginosa, indicating that LDH is only stable in shorter incubation times in infected cultures.
Figure 6 shows the kinetics of pro-inflammatory cytokines detected via ELISA. The advantage of an infected co-culture of CFBE41o- and THP-1 cells was observed with the higher secretions of pro-inflammatory cytokines. The secretion of some pro-inflammatory cytokines was either similar (IL-6) or higher (IL-8, TNF-α, IL-1β) in the infected co-culture (Figure 6C) than in the corresponding monocultures (Figures 6A-B). Unexpectedly, some cytokines in THP-1 monocultures (Figure 6B) are downregulated in infected samples (Il-8, TNFα, IL-1β).
Figure 7 demonstrates the release of cytokines in mono- and co-cultures upon infection and treatment with tobramycin measured via fluorescence activated cell sorting (FACS). The secretion of the pro-inflammatory cytokine IL-8 (Figure 7A) and the anti-inflammatory cytokine IL-10 (Figure 7F) was higher in the co-cultures of epithelial cells and macrophages, compared to the monocultures. However, for all other cytokines (IL-1 α, IL-12p40, IL-23 and GM-CSF) (Figures 7B–E), the levels of cytokine secretion were not higher in the co-culture that in the respective monocultures.
Figure 1: Cross-sections and apical views of the uninfected epithelial-macrophage co-culture. (A) Cross views of uninfected 24 h epithelial-macrophage co-culture. CFBE41o– stained red, THP-1 macrophages in yellow and nuclei in blue (DAPI). (B) Apical views of the uninfected CFBE41o- monolayer immuno-stained for ZO-1 (red). DAPI: nuclei. Scale bars: 50 µm. Please click here to view a larger version of this figure.
Figure 2: Cross-sections and apical views of the infected epithelial-macrophage co-culture. (A) Cross views and (B) apical view of epithelial-macrophage co-culture at 6 h post-infection (hpi) with P. aeruginosa PAO1-GFP. CFBE41o– stained in red, THP-1 macrophages in yellow, nuclei in blue (DAPI) and P. aeruginosa PAO1-GFP in green. (B) Apical views of the 6 h infected CFBE41o- monolayer. Scale bars: 50 µm. Please click here to view a larger version of this figure.
Figure 3: Kinetics of macrophage transmigration and bacteria uptake visualized by cross-section of the 3D model. PAO1-GFP infection kinetics in monocultures of THP-1 macrophages (A–C) or co-culture (D–F). THP-1 macrophages are stained in red, nuclei of epithelial cells in blue (DAPI), and P. aeruginosa in green (GFP). Each figure is divided into apical and basolateral sides, the space in between is considered to be the membrane, which is empty or occupied by the CFBE41o– confluent layer (D–F). Inserts in the figures show bacteria uptake by macrophages at different times (A–F). Scale bars: 50 µm. Please click here to view a larger version of this figure.
Figure 4: Characterization of PAO1-GFP survival in tobramycin-treated co-culture. (A–D) Confocal micrographs co-cultures with and without treatment. (A) Untreated co-culture after 6 h of infection. (B) Infected co-culture treated with tobramycin 6 µg/mL (Tob) for 6 h. (C) Untreated co-culture 20 h post-infection, (D) infected co-culture treated with tobramycin 6 µg/mL for 20 h. Nuclei stained with DAPI (blue), macrophages (red) and P. aeruginosa GFP (green). (E) Colony-forming units (CFU) of adherent/internalized bacteria after 6 and (F) 20 h with tobramycin 6 µg/mL treatment. Empty membrane insert was used as an abiotic substrate to grow PAO1-GFP. Two-way ANOVA with Tukey’s multiple comparisons test (# no colonies) was used, *p < 0.05; ***p < 0.001; ****p < 0.0001; ns: not significant. Error bars indicate standard deviation, n = 9–27 replicates of 3–9 independent experiments. Please click here to view a larger version of this figure.
Figure 5: Barrier integrity and evaluation of the viability of mono- and co-culture. The following co-culture conditions were assessed: uninfected (gray bars), infected (green bars), or infected and treated with tobramycin (blue bars). (A) Transepithelial electrical resistance after 6 h and (B) 20 h of infection in mono-cultures (CFBE41o– and THP-1) and co-culture. (C) Cytotoxicity of mono- and co-culture measured via LDH release 6 h post-infection. Two-way ANOVA with Tukey’s multiple comparisons test was used; *p < 0.05; ****p < 0.0001; ns: not significant. Error bars indicate standard deviation; n = 9 replicates of three independent experiments. Please click here to view a larger version of this figure.
Figure 6: Kinetics of cytokine release of uninfected and infected mono- and co-culture supernatants assessed via ELISA. ELISA was done according to the kit manufacturer's protocol. (A) CFBE41o-, (B) THP-1, and (C) co-culture releasing IL-8, TNF-α, IL-1β, and IL-6. Error bars indicate standard deviation. n = 6 replicates of 2 independent experiments. Please click here to view a larger version of this figure.
Figure 7: Supernatant results of cytokine panel measured via FACS with and without tobramycin 6 µg/mL for 6 h post-infection. Supernatants of mono- and co-culture after 6 h post-infection used to analyze the respective cytokines IL-8 (A), IL-1α (B), IL12p40 (C), IL-23 (D), GM-CSF (E) and IL-10 (F). Error bar indicates standard deviation, n = 9 replicates of 3 independent experiments. Please click here to view a larger version of this figure.
Supplementary Figure S1: Control experiments for critical steps of the protocol. (A, B) Micrographs of CFBE41o- cells in 24-well plates grown for 2 days at density of 2 x 105 cells/well. (A) CFBE41o- cells in PBS for 30 min, and (B) water-treated cells after 30 min after scraping with a pipette. (C) Viability of mammalian cells after centrifugation. CFBE41o- cells were removed from T75 cell culture flask as described in step 1.1.1 and 1.1.2. 100 µL of resulting cell suspension was analyzed in 10 mL isotonic solution. An automated cell counter was used to assess the viability of single cells. Then, respective cell suspensions were centrifuged at 300 x g for 4 min, re-suspended and counted again. Error bars indicate standard deviation, n = 6 different flasks of 2 individual experiments. (D) Viability of PAO1-GFP after centrifugation. PAO1-GFP bacteria were diluted to OD = 0.01 in cell medium. CFU was assessed via a 10-fold dilution row and LB plates incubated overnight at 30 °C. Respective plastic tubes were centrifuged at 21,250 x g for 10 min and re-suspended in medium. CFU was assessed accordingly again. Two-tailed student's t-test, * p < 0.033. Error bar indicates standard deviation, n = 6 of 2 experiments. (E) Viability of bacteria after freezing. PAO1-GFP bacteria were prepared as in (D) and CFU was analyzed, then plastic tubes were frozen for one day at -20 °C and thawed to assess CFU again. Two-tailed student´s t-test, *** p < 0.001. Error bars indicate standard deviation, n = 6 of two experiments. Please click here to download this file.
Supplementary Figure S2: Control experiments to assess LDH behavior and influence of tobramycin. (A) Control experiment to assess cytotoxicity after 20 h of incubation with 6 µg/mL tobramycin. Mono- and co-culture was done as described in the protocol, but cells were grown for 2 days on 24-well plates and THP-1 cells were seeded apically. Cells with 6 µg/mL tobramycin or controls were incubated for 20 h. One-Way ANOVA, Tukey's multiple comparisons test, *** p < 0.001. Error bar indicates standard deviation, n = 6 of 2 experiments (CFBE41o-), n = 3 of one experiment (THP-1 and co-culture). (B) Control-ELISA of supernatants of mono- and co-culture with/without tobramycin. Cell culture was done according to (A) to show no cytokine release compared to controls for all conditions. ELISA was done in step 7.1 and 7.2, 10 µg/mL (LPS) was added as control, IL-8 release for LPS-treated controls containing THP-1 was higher than detectable. Two-Way ANOVA, Tukey's multiple comparisons test, ns p > 0.12; * p < 0.033; *** p < 0.001. Error bars indicate standard deviation, n = 6 of two experiments, n = 3 of one experiment (LPS control). (C) LDH degradation due to excessive PAO1-GFP proliferation. LDH was added at concentration of 1 U/mL to the MEM Medium. Either LDH medium or control medium was used to dilute cells to OD = 0.01 (corresponds to 1 x 108 CFU/mL) and then incubated for 20 h. LDH assay was done as described in section 6. One-Way ANOVA, Tukey´s multiple comparisons test, ns p > 0.12; ***p < 0.001. Error bar indicates standard deviation, n = 8–9 of three individual experiments. Please click here to download this file.
This paper describes a protocol for a 3D co-culture of the infected airways, constituted by the human cystic fibrosis bronchial epithelial cell line CFBE41o- and the human monocyte-derived macrophage cell line THP-1. The protocol allows the assessment of epithelial barrier integrity, macrophage transmigration, bacteria survival, and inflammation, which are important parameters when testing drug efficacy and host-responses simultaneously. The novelty in the model lies within the incorporation of epithelial cells (i.e. human CF cell line and macrophages) with acute bacterial infection (i.e. P. aeruginosa). The acute infection in the epithelial cells is demonstrated to be controlled by an antibiotic (i.e. tobramycin). Besides the use of a human CF cell line, the entire model is set up at ALI conditions, which is considerably closer to the physiological conditions in CF. The use of a CF cell line implements some of the characteristics of the disease in the model. The mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) is directly related to the dysregulation of epithelial fluid transport in the lungs. Furthermore, mutations in the CF gene, such as the ΔF508, result in thick mucus, with inflammation and severe lung damage upon infection with P. aeruginosa4. These pathological manifestations caused by dysfunctional CFTR potentially involve autophagy impairment as an important cellular mechanism associated with the pathogenesis of CF lung disease18. However, the CFBE41o– fail to secret mucus, which is a limitation of this cell line. If it is intended to study the role of mucus more specifically, the protocol can be adapted by using other bronchial cell lines (e.g., Calu-3).
One critical step to set up this protocol is the combination of epithelial and immune cells and the subsequent infection with P. aeruginosa at ALI. The infection of CFBE41o– by P. aeruginosa in vitro has already been described, mainly using a flow-cell chamber, supplemented with arginine in the culture media, to improve epithelial cell survival and support biofilm formation19. The present protocol aimed for a new model using only human cells, which moreover, could be grown at ALI on permeable well plate inserts for higher sample throughput. The inclusion of THP-1 differentiated macrophages as a human immortalized cell line, instead of being dependent on obtaining reproducible primary cells from donors, is another advantage of our model. By adding these macrophages to the basolateral side of permeable membrane support, it was observed that macrophages protruded and eventually transmigrated to the apical side of the filter-grown epithelial barrier. A variation of this protocol could be the addition of macrophages directly on the apical side on top of the epithelial cells, as described by Kletting et al.14. The co-culture of non-human immune and lung cells has already been described before. Ding et al.10 used mouse Lewis lung carcinoma cells on permeable insert supports in combination with macrophages on the basolateral side and infected with S. aureus, another critical pathogen of chronic infection in CF patients. However, in this study, there was no focus on cystic fibrosis or to use the co-culture as a platform for the evaluation of drug efficacy. Our protocol can be adapted for other bacterial infections, such as Staphylococcus aureus, Mycobacterium abscessus, or Burkholderia cepacia— important pathogens in CF lung.
Another critical step is the addition of THP-1 macrophages to the cells by flipping the permeable inserts upside-down (section 2). This is crucial to assess macrophage transmigration through the well to the side of infection. The later imaging process from the 3D models with z-stacks, and cross-section view, can be performed to observe the inside of macrophages and detect bacteria uptake (Figure 3). At 1 hpi, bacteria applied on the apical side migrate through the membrane, while macrophage migration and uptake only take place at 3 hpi. Therefore after 1 h of infection, it was appropriate to start the treatment with tobramycin and have the possibility to address both host cell and bacteria survival for a long period (20 h). In the course of the protocol, maintaining sterility is a critical issue due to the multitude of steps that each carry the risk of contamination. Nevertheless, experienced cell-culture personnel will be able to follow this protocol after appropriate preparation and training. Cell medium should be regularly checked for contamination, preferably after all critical steps.
As with any model, the infected co-culture also has some limitations; for instance, the integration of the macrophage-like cells. Here, it was important to have macrophages on the basolateral side; however, the manipulation of the insert with a previously grown epithelial layer may have provided early damage and disturbances to the co-culture. Although, the permeable support model provided high-throughput characteristics, which has not been observed in previous co-cultures of the CF infected lung20,21. With that, further experiments need to assess the limitations of using THP-1 as macrophage substitute. While this cell line is widely used, it is less responsive to LPS22 and it lacks full activation and the entire population is not differentiated from monocytes to macrophage-like cells23. Another limitation is the lack of other key components in CF infection and drug delivery. The CFBE41o– cell line does not possess cilia nor does it produce mucus, which usually happens 20-30 days of cell culture at ALI. As this was not the case for CFBE41o– cell line, we used the cells after seven days when a tight epithelial barrier was formed. Mucociliary clearance alters the residence conditions for either microbes24 or drug particles9,25 and in vitro models assessing lung deposition should take this into account. Differently from what is observed by other cells, the tissue culture inserts coating with an extracellular matrix material (like fibronectin or collagen I) do not show a significant difference for CFBE41o–, for instance in TEER26. Therefore, the permeable filters were not coated with an extracellular matrix material in this protocol.
With the protocol described here, mono and co-cultures after 6 h infection provide sufficient cytokine release to be used as a measurement in future drug testing. The co-culture brings an advantage of cell cooperation in modeling immune response. The inefficacy of tobramycin in reducing inflammation was expected since not all bacteria were eliminated during the treatment (Figure 4E, F). Nevertheless, modeling the response to tobramycin in a CF model is crucial, as tobramycin (in higher concentrations) can be effective in P. aeruginosa inhibition, even on biofilm19,27. One possibility for further use of this protocol is to integrate anti-inflammatory drugs in the treatment. The overall recommendation regarding inflammatory responses would be to use the short duration treatment (6 h), which still has the host cell and bacteria present. After this time point, the host cells are destroyed in untreated samples. Both ELISA and FACS could be used to measure the release of cytokines. Finally, if the samples are stored longer than 15 days at -80 °C, it is recommended to check the reliability of the cytokines by using, for instance, positive control of fresh samples (e.g. cells stimulated with LPS).
Some modifications of the protocol are possible. For example, the current protocol can be expanded to the application of nebulized drugs (step 3.6). This is necessary to model pulmonary drug delivery via oral inhalation. Nebulization of water-soluble drugs, like tobramycin, or nano-carriers thereof, such as liposomal colistin, is relatively straight forward by commercially available devices routinely used in the clinic. Also, there are several commercially available devices to deposit aerosols onto cell culture inserts. In addition, as the model described here is based on permeable membrane supports, it could also be adopted to some contemporary microfluidic (e.g. “lung on a chip”) devices, for example, to study the influence of breathing and the related mechanical stretching and changes in the airflow. Moreover, this protocol could be modified by the addition of mucus or replacement by primary cells depending on the scientific question to be addressed. Another interesting next step would be the testing of nanomedicines, especially as nanotechnology is making progress in the development of novel anti-infectives28, CF correctors29 and co-delivery of antibiotics and pathoblockers30. Overall, the current protocol may be perceived as useful in assessing bacterial survival upon antibiotic treatment in a complex system, together with some host-related readouts: cell cytotoxicity, epithelial barrier integrity, macrophage transmigration and inflammatory response. These are essential parameters for drug development.
The authors have nothing to disclose.
This work received funding from the European Union’s HORIZON 2020 Program for research, technological development, and demonstration under grant agreement no. 642028 H2020-MSCA-ITN-2014, NABBA – Design, and Development of advanced Nanomedicines to overcome Biological Barriers and to treat severe diseases. We thank Dr. Ana Costa and Dr. Jenny Juntke for the great support on the development of the co-culture, Olga Hartwig, for the scientific illustration, Anja Honecker, for ELISA assays, Petra König, Jana Westhues and Dr. Chiara De Rossi for the support on cell culture, analytics, and microscopy. We also thank Chelsea Thorn for proofreading our manuscript.
Accutase | Accutase | AT104 | |
Ampicillin | Carl Roth, Germany | HP62.1 | |
CASY TT Cell Counter and Analyzer | OLS Omni Life Sciences | – | |
CellTrace Far Red | Thermo Fischer | C34564 | |
Centrifuge Universal 320R | Hettich, Germany | 1406 | |
CFBE41o– cells | 1. Gruenert Cell Line Distribution Program 2. Sigma-Aldrich |
1. gift from Dr. Dieter C. Gruenert 2. SCC151 |
|
Chopstick Electrode Set for EVOM2, 4mm | World Precision Instruments, Sarasota, USA | STX2 | |
Confocal Laser-Scanning Microscope CLSM | Leica, Mannheim, Germany | TCS SP 8 | |
Cytokines ELISA Ready-SET-Go kits | Affymetrix eBioscience, USA | 15541037 | |
Cytokines Panel I and II | LEGENDplex Immunoassay (Biolegend, USA). | 740102 | |
Cytotoxicity Detection Kit (LDH) | Roche | 11644793001 | |
D-(+) Glucose | Merck | 47829 | |
Dako Fluorescence Mounting Medium | DAKO | S3023 | |
DAPI (4′,6-diamidino-2-phenylindole) | Thermo Fischer | D1306 | |
Epithelial voltohmmeter | World Precision Instruments, Sarasota, USA | EVOM2 | |
Falcon Permeable Support for 12 Well Plate with 3.0μm Transparent PET Membrane, Sterile | Corning, Amsterdam, Netherlands | 353181 | |
Fetal calf serum | Lonza, Basel, Switzerland | DE14-801F | |
Goat anti-mouse (H+L) Cross-adsorbed secondary Antibody, Alexa Fluor 633 | Invitrogen | A-21050 | |
L-Lactate Dehydrogenase (LDH), rabbit muscle | Roche, Mannheim, Germany | 10127230001 | |
LB broth | Sigma-Aldrich, Germany | L2897-1KG | |
MEM (Minimum Essential Medium) | Gibco Thermo Fisher Scientific Inc. | 11095072 | |
Non-Essential Amino Acids Solution (100X) | Gibco Thermo Fisher Scientific Inc. | 11140050 | |
P. aeruginosa strain PAO1 | American Type Culture Collection | 47085 | |
P. aeruginosa strain PAO1-GFP | American Type Culture Collection | 10145GFP | |
Paraformaldehyde Aqueous Solution -16% | EMS DIASUM | 15710-S | |
Phosphate buffer solution buffer | Thermo Fischer | 10010023 | |
Petri dishes | Greiner | 664102 | |
Phorbol 12-myristate 13-acetate (PMA) | Sigma, Germany | P8139-1MG | |
Precision Cover Glasses | ThorLabs | CG15KH | |
Purified Mouse anti-human ZO-1 IgG antibody | BD Transduction Laboratories | 610966 | |
Roswell Park Memorial Institute (RPMI) 1640 medium | Gibco by Lifetechnologies, Paisley, UK | 11875093 | |
Soda-lime glass Petri dish, 50 x 200 mm (height x outside diameter) | Normax, Portugal | 5058561 | |
Saponin | Sigma-Aldrich, Germany | S4521 | |
T75 culture flasks | Thermo Fischer | 156499 | |
THP-1 cells | Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Braunschweig, Germany) | No. ACC-16 | |
Tobramycin sulfate salt | Sigma | T1783-500MG | |
Trypsin-EDTA 0.05% | Thermo Fischer | 25300054 | |
Tween80 | Sigma-Aldrich, Germany | P1754 |